Stonegate Capital Partners has initiated coverage on NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage life sciences company focused on developing central nervous system therapeutics. The coverage highlights the company’s strategy to overcome the blood-brain barrier, a significant challenge in treating neurological conditions.
NeOnc’s pipeline is centered on its lead asset, NEO100, a patented, pure pharmaceutical compound produced via proprietary synthesis to ensure pharmaceutical-grade purity and reproducibility. The company’s approach utilizes intranasal administration, designed to access the brain via the olfactory and trigeminal pathways. This method offers a non-invasive route intended to improve patient adherence and enable more direct delivery of therapeutics to the central nervous system.
Stonegate views NeOnc as a differentiated platform, noting favorable tolerability with prolonged dosing and identifying multiple near-term catalysts. The firm points to positive Phase 1/2a results for NEO100 that were announced in December. A key upcoming milestone is the NEO100 Phase 2a top-line readout, which is expected in mid-2026. Additionally, the closing and funding of the Quazar Investment is anticipated in the near term. To view the full announcement, including downloadable images and more information, visit https://www.stonegateinc.com.
The initiation of coverage by an advisory firm like Stonegate Capital Partners brings increased visibility to NeOnc’s clinical programs. The focus on a non-invasive delivery method for CNS drugs addresses a persistent hurdle in neurology and oncology treatments, where effective drug delivery to the brain is often limited. The anticipated 2026 data readout for NEO100 represents a significant inflection point for evaluating the compound’s efficacy and potential commercial pathway.
This news story relied on content distributed by Reportable. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Stonegate Capital Partners Initiates Coverage on NeOnc Technologies, Citing CNS Therapeutic Pipeline and 2026 Catalyst.